Advancing Cancer Therapy with Radiation Biology Insights
Official title: Advancing Cancer Therapy through Groundbreaking Research in Radiation Biology
Funded at Roswell Park Cancer Institute Corp · NIH-11402656 · Data updated 2026-11-12
A cancer research program is exploring how to maximize the benefits of radiation therapy while reducing its side effects, using advanced models to understand tumor and normal tissue responses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | January 16, 2016 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $868,258 |
| NIH project number | 5R35CA197616-12 |
| Project ID | NIH-11402656 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced sarcoma or other cancers treated with radiation who may benefit from reduced toxicity and improved tumor response.
✕Less likely to help
Patients whose cancer type or biology do not respond to the proposed radio-sensitivity approaches may not experience benefit.
What this research studies
This program studies how radiation affects both cancer and surrounding tissues, aiming to widen the safe and effective range of treatment. Researchers use cutting-edge genetic tools and mouse models to trace tumor evolution and uncover targets that could prevent metastasis. The work connects biology of sarcoma with practical questions about improving radiation outcomes for patients. It may also point to new strategies to protect normal tissues during therapy. The effort is led by a sarcoma-focused radiation oncologist and collaborators at Roswell Park Cancer Institute.
Why it matters
Potential benefit: If successful, patients could experience better tumor control with fewer and less severe radiation-related side effects.
How similar studies have gone: Previous work using CRISPR-enabled models has identified regulators of metastasis and radiosensitivity, supporting the potential for meaningful advances.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Kirsch, David Guy — Roswell Park Cancer Institute Corp
- Study coordinator: Kirsch, David Guy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.